Okuma Y[au] - Search Results

Year	Number of Results
1963	1
1964	1
1965	1
1967	2
1969	4
1970	1
1971	5
1975	1
1976	4
1979	2
1980	1
1981	2
1982	1
1983	2
1984	2
1985	1
1986	4
1987	4
1988	4
1989	3
1990	1
1991	4
1992	2
1993	3
1995	4
1996	6
1997	3
1998	10
1999	7
2000	12
2001	9
2002	17
2003	14
2004	14
2005	16
2006	15
2007	14
2008	9
2009	10
2010	12
2011	14
2012	22
2013	21
2014	26
2015	30
2016	28
2017	23
2018	29
2019	34
2020	25
2021	41
2022	24

1

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.

Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N. Sato J, et al. Among authors: okuma y. Lancet Oncol. 2020 Jun;21(6):843-850. doi: 10.1016/S1470-2045(20)30162-5. Lancet Oncol. 2020. PMID: 32502444 Clinical Trial.

2

Freezing of gait and fall detection in Parkinson's disease using wearable sensors: a systematic review.

Silva de Lima AL, Evers LJW, Hahn T, Bataille L, Hamilton JL, Little MA, Okuma Y, Bloem BR, Faber MJ. Silva de Lima AL, et al. Among authors: okuma y. J Neurol. 2017 Aug;264(8):1642-1654. doi: 10.1007/s00415-017-8424-0. Epub 2017 Mar 1. J Neurol. 2017. PMID: 28251357 Free PMC article. Review.

3

IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.

Nishio M, Saito H, Goto K, Watanabe S, Sueoka-Aragane N, Okuma Y, Kasahara K, Chikamori K, Nakagawa Y, Kawakami T. Nishio M, et al. Among authors: okuma y. Cancer Sci. 2021 Apr;112(4):1534-1544. doi: 10.1111/cas.14817. Epub 2021 Feb 9. Cancer Sci. 2021. PMID: 33462883 Free PMC article. Clinical Trial.

4

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.

Masuda K, Horinouchi H, Tanaka M, Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y. Masuda K, et al. Among authors: okuma y. J Cancer Res Clin Oncol. 2021 Jan;147(1):245-251. doi: 10.1007/s00432-020-03329-0. Epub 2020 Jul 23. J Cancer Res Clin Oncol. 2021. PMID: 32705363 Free PMC article. Clinical Trial.

5

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.

Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: okuma y. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685

6

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.

Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benlaïfaoui M, Mimpen I, Terrisse S, Derosa L, Zitvogel L, Routy B, Okuma Y. Hakozaki T, et al. Among authors: okuma y. Cancer Immunol Res. 2020 Oct;8(10):1243-1250. doi: 10.1158/2326-6066.CIR-20-0196. Epub 2020 Jul 27. Cancer Immunol Res. 2020. PMID: 32847937

7

Retraction Note to: Effect of Adrenaline on Cerebral Blood Oxygenation Measured by NIRS in a Rat Asphyxia Cardiac Arrest Model.

Okuma Y, Yagi T, Yin T, Kiguchi T, Iwami T, Becker LB, Shinozaki K. Okuma Y, et al. Adv Exp Med Biol. 2021;1269:C1. doi: 10.1007/978-3-030-48238-1_63. Adv Exp Med Biol. 2021. PMID: 34855163 No abstract available.

8

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.

Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: okuma y. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.

9

Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma.

Kitadai R, Okuma Y. Kitadai R, et al. Among authors: okuma y. Cancers (Basel). 2021 Oct 19;13(20):5239. doi: 10.3390/cancers13205239. Cancers (Basel). 2021. PMID: 34680386 Free PMC article. Review.

10

Commentary: Progressive Encephalomyelitis with Rigidity and Myoclonus and Myasthenia Gravis Comorbid Status with Thymoma.

Balint B, Ogawa T, Ogaki K, Daida K, Nishimaki T, Ando M, Kawajiri S, Wada R, Noda K, Hattori N, Okuma Y, Barsottini O. Balint B, et al. Among authors: okuma y. Mov Disord Clin Pract. 2021 Sep 3;8(Suppl 1):S14-S15. doi: 10.1002/mdc3.13303. eCollection 2021 Aug. Mov Disord Clin Pract. 2021. PMID: 34514037 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results